MedTrace Logo

Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)

NCT03824197 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-08-02

No results posted yet for this study

Summary

Until now there is no medical treatment and/or intervention that can slow, stop or reverse the underlying neurodegenerative of Alzheimer's disease (AD). The goal of this study is to demonstrate "Oleocanthal rich-extra-virgin olive oil (EVOO) consumption stops or delay mild cognitive impairment conversion to AD by restoring the blood-brain barrier (BBB) function in humans".

Specific Aims:

1. Evaluate effect of EVOO on the brain function by functional MRI (fMRI) imaging, and BBB function by dynamic contrast-enhanced MRI (DCE-MRI).
2. Evaluate effect of EVOO on cognitive function and on selected biomarkers

Conditions

  • Alzheimer Disease
  • Cerebral Amyloid Angiopathy

Interventions

OTHER

EVOO

Extra-virgin olive oil that is rich with oleocanthal and other phenols.

OTHER

OO

Olive oil low in oleocanthal and other phenols.

Sponsors & Collaborators

  • Auburn University

    lead OTHER

Principal Investigators

  • Amal Kaddoumi, PhD · Auburn University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-07
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03824197 on ClinicalTrials.gov